Literature DB >> 8043866

Clinical importance of extraordinary integration patterns of human T-cell lymphotropic virus type I proviral DNA in adult T-cell leukemia/lymphoma.

Y Shimamoto1, K Suga, K Shibata, M Matsuzaki, H Yano, M Yamaguchi.   

Abstract

The proviral DNA of human T-cell lymphotrophic virus type I (HTLV-I) is known to be integrated monoclonally in the malignant cells of adult T-cell leukemia/lymphoma (ATL), which is a peripheral T-cell malignancy caused by this virus. We studied the relationship between the integration patterns of HTLV-I and clinical characteristics in 89 patients with ATL. The proviral DNA of HTLV-I was examined by the standard Southern blot analysis using the endonucleases EcoRI and Pst I. One clear band of greater than 9 kb was detected in most of the patients (83 case) when cellular DNA was digested with EcoRI. On the other hand, extraordinary integration patterns of HTLV-I proviral DNA were detected in 6 patients; 3 of them showed two bands, while the other 3 showed one band smaller than 9 kb. When cellular DNA was digested with PstI, the band patterns of these patients were quite different from those of typical patients. The patients with the extraordinary integration patterns had clinical characteristics dissimilar to those of the other 83 patients with the ordinary integration pattern. The patients with two bands by EcoRI digestion always had severe hypoxemia with extremely high levels of serum lactate dehydrogenase at first presentation and showed peculiar organ infiltrations, such as retina and muscle, which were less frequent in the other ordinary 83 patients. They all died within 8 months after the onset. In contrast, the patients with one smaller band by EcoRI digestion always had small and mature T lymphocytes with bilobulated nuclei without lymphadenopathy and showed a favorable clinical course, which was uncommon in the ordinary cases. They were alive 20 to 38 months after diagnosis. Rearranged bands of the T-cell receptor gene were detected in all patients with unusual integration. These findings indicate that the integration patterns of HTLV-I proviral DNA have a clinical implication and may be one of the explanations for heterogeneity in the behavior of this disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8043866

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Human T-cell lymphotropic virus-associated primary gastric lymphoma.

Authors:  H Sakata; R Iwakiri; T Koyama; T Yoshida; K Okamoto; K Miyazaki; T M Mizuguchi; S Kudo; O Tokunaga; K Fujimoto
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

Review 2.  The molecular genetics of hematologic malignancies.

Authors:  A Bagg
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

3.  In situ polymerase chain reaction detection of HTLV-I provirus and expression of the p53 tumor suppressor gene in infiltrating cells in skeletal muscle from a patient with adult T cell leukemia.

Authors:  I Higuchi; K Hashimoto; N Kashio; S Izumo; H Matsuoka; M Nakagawa; M Osame
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

4.  Correlation between immunophenotypic diversity and clinical features in B-cell lymphoblastic lymphoma.

Authors:  K Shibata; Y Shimamoto; H Yamada; M Miyahara; N Fukushima; H Yano
Journal:  Ann Hematol       Date:  1995-12       Impact factor: 3.673

5.  Mantle cell lymphoma with the features of mucosa-associated lymphoid tissue (MALT) lymphoma in an HTLV-I-seropositive patient.

Authors:  K Shibata; Y Shimamoto; S Nakano; M Miyahara; H Nakano; M Yamaguchi
Journal:  Ann Hematol       Date:  1995-01       Impact factor: 3.673

6.  Clinical and cytopathological characteristics of HTLV-1+ hodgkin lymphoma.

Authors:  Katsumi Kobata; Shoichi Kimura; Yasuhito Mihashi; Hiromi Iwasaki; Shuichi Nonaka; Shinji Matsumoto; Yasushi Takamatsu; Ilseung Choi; Shigeto Kawauchi; Kenji Ishitsuka; Morishige Takeshita
Journal:  Cancer Med       Date:  2020-06-28       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.